Table 1.
TNF inhibitors and endothelial function in patients with psoriasis and PsA.
| First Author | Year | Disease | Number of Patients Treated with TNF-Inhibitors | Duration of Treatment between Assessments | Drug | Improvement of Flow Mediated Dilatation | Improvement in Pulse Wave Velocity | Impaired Progression of Intima Media Thickness |
|---|---|---|---|---|---|---|---|---|
| Avgerinou [128] | 2011 | Psoriasis | 14 | 12 weeks | ADA | YES | NO | NA |
| Pina [129] | 2016 | Psoriasis | 29 | 6 months | ADA | YES | YES | NA |
| Tam [130] | 2011 | PsA | 11 | 3 months | TNF inhibitors | NA | NA | YES |
| Tam [130] | 2011 | PsA | 9 | 2 years | TNF inhibitors | NA | NA | NO |
| Di Minno [131] | 2011 | PsA | 120 | 52, 24 months (mean, SD) | ADA, ETN, IFX | NA | NA | YES |
| Ramonda [132] | 2014 | PsA | 32 | 2 years | ADA, ETN, IFX | NO | NA | NO |
| Mazzoccoli [133] | 2010 | PsA, RA | 36 | 8–12 weeks | ETN, IFX | YES | NA | NO |
| Angel [134] | 2011 | PsA, RA, AS | 17 | 8 weeks (previously treated for ≥1 year) | IFX | NA | NO | NA |
| Angel [135] | 2012 | PsA, RA, AS | 36 | 1 year | ADA, ETN, IFX | NA | YES | YES |
| Angel [136] | 2010 | PsA, RA, AS | 35 | 3 months | ADA, ETN, IFX | NA | YES | NA |
ADA: adalimumab; AS: ankylosing spondylitis; ETN: etanercept; IFX: infliximab; NA: not assessed; PsA: psoriatic arthritis; RA: rheumatoid arthritis; TNF: tumor necrosis factor α.